Cyclooxygenase-2 selective inhibitors and prostate cancer: what is the clinical benefit?
DuBois
Raymond N
RN
D000068579:Celecoxib; D052246:Cyclooxygenase 2 Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000097:blood / Q000628:therapy*; D011720:Pyrazoles / Q000009:adverse effects / Q000627:therapeutic use*; D012306:Risk; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use*
D052246:Cyclooxygenase 2 Inhibitors; D011720:Pyrazoles; D013449:Sulfonamides; D017430:Prostate-Specific Antigen; D000068579:Celecoxib